CanSino’s covax to continue advancing phase-3 trials: Report

Beijing, Feb 3 : Chinas CanSino Biologics Inc.has got green light to continue phase-3 trials of its Covid-19 vaccine with the support of findings of an independent data monitoring committee, said media reports.

The independent committee "found the drugmakers Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," the report said.

No adverse events related to the vaccine had occurred, according to the Xinhua news agency.The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc.and the Academy of Military Sciences in China.CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with Chinas Ministry of Science and Technology, said in September last year.